메뉴 건너뛰기




Volumn 12, Issue 6, 2012, Pages 438-443

High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk

Author keywords

Acute myeloid leukemia (AML); Cytogenetic analysis; Elderly; Gemtuzumab ozogamicin

Indexed keywords

CYTARABINE; GEMTUZUMAB OZOGAMICIN;

EID: 84869401307     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.05.007     Document Type: Article
Times cited : (9)

References (16)
  • 1
    • 78649486856 scopus 로고    scopus 로고
    • Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
    • H. Kantarjian, F. Ravandi, S. O'Brien Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia Blood 116 2010 4422 4429
    • (2010) Blood , vol.116 , pp. 4422-4429
    • Kantarjian, H.1    Ravandi, F.2    O'Brien, S.3
  • 2
    • 34249810897 scopus 로고    scopus 로고
    • Acute myeloid leukemia and myelodysplastic syndromes in older patients
    • E. Estey Acute myeloid leukemia and myelodysplastic syndromes in older patients J Clin Oncol 25 2007 1908 1915
    • (2007) J Clin Oncol , vol.25 , pp. 1908-1915
    • Estey, E.1
  • 3
    • 66149148673 scopus 로고    scopus 로고
    • Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
    • G. Juliusson, P. Antunovic, A. Derolf Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry Blood 113 2009 4179 4187
    • (2009) Blood , vol.113 , pp. 4179-4187
    • Juliusson, G.1    Antunovic, P.2    Derolf, A.3
  • 4
    • 0035397980 scopus 로고    scopus 로고
    • Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
    • E.L. Sievers, R.A. Larson, E.A. Stadtmauer Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse J Clin Oncol 19 2001 3244 3254
    • (2001) J Clin Oncol , vol.19 , pp. 3244-3254
    • Sievers, E.L.1    Larson, R.A.2    Stadtmauer, E.A.3
  • 5
    • 25144485908 scopus 로고    scopus 로고
    • Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
    • R.A. Larson, E.L. Sievers, E.A. Stadtmauer Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence Cancer 104 2005 1442 1452
    • (2005) Cancer , vol.104 , pp. 1442-1452
    • Larson, R.A.1    Sievers, E.L.2    Stadtmauer, E.A.3
  • 6
    • 27144464151 scopus 로고    scopus 로고
    • Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: Final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
    • S. Amadori, S. Suciu, R. Stasi Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups Leukemia 19 2005 1768 1773
    • (2005) Leukemia , vol.19 , pp. 1768-1773
    • Amadori, S.1    Suciu, S.2    Stasi, R.3
  • 7
    • 77950796567 scopus 로고    scopus 로고
    • Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)
    • S. Amadori, S. Suciu, D. Selleslag Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19) Br J Haematol 149 2010 376 382
    • (2010) Br J Haematol , vol.149 , pp. 376-382
    • Amadori, S.1    Suciu, S.2    Selleslag, D.3
  • 8
    • 77957711298 scopus 로고    scopus 로고
    • Preliminary results of Southwest Oncology Group Study SO106: An international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy to previously untreated acute myeloid leukemia
    • S. Petersdorf, K. Kopecky, R.K. Stuart Preliminary results of Southwest Oncology Group Study SO106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy to previously untreated acute myeloid leukemia Blood 114 2009 326a
    • (2009) Blood , vol.114
    • Petersdorf, S.1    Kopecky, K.2    Stuart, R.K.3
  • 9
    • 10744230708 scopus 로고    scopus 로고
    • A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia
    • W.J. Kell, A.K. Burnett, R. Chopra A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia Blood 102 2003 4277 4283
    • (2003) Blood , vol.102 , pp. 4277-4283
    • Kell, W.J.1    Burnett, A.K.2    Chopra, R.3
  • 10
    • 79952099282 scopus 로고    scopus 로고
    • Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial
    • A.K. Burnett, R.K. Hills, D. Milligan Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial J Clin Oncol 29 2011 369 377
    • (2011) J Clin Oncol , vol.29 , pp. 369-377
    • Burnett, A.K.1    Hills, R.K.2    Milligan, D.3
  • 11
    • 84860121680 scopus 로고    scopus 로고
    • The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: Results of the UK NCRI AML16 randomized trial
    • A.K. Burnett, R.K. Hills, A.E. Hunter The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial Blood 118 2011 582a
    • (2011) Blood , vol.118
    • Burnett, A.K.1    Hills, R.K.2    Hunter, A.E.3
  • 12
    • 84860176499 scopus 로고    scopus 로고
    • Fractionated doses of gemtuzumab ozogamicin (GO) combined to standard chemotherapy (CT) improve event-free and overall survival in newly-diagnosed de novo AML patients aged 50-70 years old: A prospective randomized phase 3 trial from the acute leukemia French association (ALFA)
    • S. Castaigne, C. Pautas, C. Terre Fractionated doses of gemtuzumab ozogamicin (GO) combined to standard chemotherapy (CT) improve event-free and overall survival in newly-diagnosed de novo AML patients aged 50-70 years old: a prospective randomized phase 3 trial from the acute leukemia French association (ALFA) Blood 118 2011 6a
    • (2011) Blood , vol.118
    • Castaigne, S.1    Pautas, C.2    Terre, C.3
  • 13
    • 77449159028 scopus 로고    scopus 로고
    • Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet
    • H. Döhner, E.H. Estey, S. Amadori Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood 115 2010 453 474
    • (2010) Blood , vol.115 , pp. 453-474
    • Döhner, H.1    Estey, E.H.2    Amadori, S.3
  • 14
    • 79956369016 scopus 로고    scopus 로고
    • Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin
    • H.F. Fernandez, Z. Sun, M.R. Litzow Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin Blood 117 2011 3506 3513
    • (2011) Blood , vol.117 , pp. 3506-3513
    • Fernandez, H.F.1    Sun, Z.2    Litzow, M.R.3
  • 15
    • 84859502851 scopus 로고    scopus 로고
    • Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: A randomized phase II trial in elderly patients
    • U. Brunnberg, M. Mohr, R. Noppeney Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients Ann Oncol 23 2012 990 996
    • (2012) Ann Oncol , vol.23 , pp. 990-996
    • Brunnberg, U.1    Mohr, M.2    Noppeney, R.3
  • 16
    • 70349451999 scopus 로고    scopus 로고
    • High-dose daunorubicin in older patients with acute myeloid leukemia
    • B. Löwenberg, G.J. Ossenkoppele, W. van Putten High-dose daunorubicin in older patients with acute myeloid leukemia N Engl J Med 361 2009 1235 1248
    • (2009) N Engl J Med , vol.361 , pp. 1235-1248
    • Löwenberg, B.1    Ossenkoppele, G.J.2    Van Putten, W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.